SALBUTAMOL

Information current as at: 1 April 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Ventolin®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Condition/indication:
(therapeutic use)
  • Asthma; Chronic obstructive pulmonary disease (COPD)
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC submission type:
New listing (Minor)
Comment:
--
Submission sponsor:
GlaxoSmithKline Australia Pty Ltd
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2019 PBAC meeting
Opportunity for consumer comment:
Open 28/08/2019 and close 09/10/2019 (see PBS Website)
PBAC meeting:
Held on 06/11/2019
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Exception applied
Lodgement of required documentation:
15/05/2020
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 19/05/2020
Status:
Finalised
Government processes:
Commenced on 09/06/2020
Medicine listed on the PBS:
01/08/2020 (see PBS schedule)

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information

Case ID: a091

Page last updated: 31 March 2026

v.9.19